Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) EBITDA Margin (2016 - 2025)

IGC Pharma (IGC) has disclosed EBITDA Margin for 16 consecutive years, with 963.35% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin fell 54296.0% to 963.35% in Q3 2025 year-over-year; TTM through Sep 2025 was 585.9%, a 47640.0% increase, with the full-year FY2025 number at 562.63%, up 40644.0% from a year prior.
  • EBITDA Margin was 963.35% for Q3 2025 at IGC Pharma, down from 488.41% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 360.91% in Q1 2025 to a low of 7721.43% in Q3 2021.
  • A 5-year average of 1871.7% and a median of 977.29% in 2024 define the central range for EBITDA Margin.
  • Biggest YoY gain for EBITDA Margin was 808621bps in 2021; the steepest drop was -650943bps in 2021.
  • IGC Pharma's EBITDA Margin stood at 1622.54% in 2021, then skyrocketed by 57bps to 695.78% in 2022, then crashed by -292bps to 2730.88% in 2023, then surged by 74bps to 718.68% in 2024, then crashed by -34bps to 963.35% in 2025.
  • Per Business Quant, the three most recent readings for IGC's EBITDA Margin are 963.35% (Q3 2025), 488.41% (Q2 2025), and 360.91% (Q1 2025).